For Follow-Up Monitoring of COVID-19 Patients in the Physician Office Laboratory
WEST CALDWELL, NJ – May 19, 2020 – Alfa Wassermann Diagnostic Technologies, LLC (AWDT) announced today the introduction of a COVID-19 Reagent Panel for follow-up care of vulnerable COVID-19 patients with underlying health conditions. Monitoring patients with liver, kidney, or cardiovascular conditions as well as those who showed abnormal levels in organ testing after contracting COVID-19 is of utmost importance. Vulnerable patients in recovery from the virus require continuous monitoring to reduce the risk of increased injury and hospitalization. By monitoring COVID-19 patients, physician office labs will receive the opportunity to help prescribe optimal care and/or applicable therapeutic options under investigation.
Alfa Wassermann Diagnostic Technologies, LLC offers a variety of assays for follow-up monitoring of liver, kidney, and cardiovascular functions for use on the ACE Alera® and ACE Axcel® Clinical Chemistry Systems. For ordering information, please contact a Business Development Manager at Alfa Wassermann Diagnostic Technologies, LLC.
About Alfa Wassermann Diagnostic Technologies, LLC
Alfa Wassermann Diagnostic Technologies, LLC is a leading provider of medical diagnostic instrumentation and reagents to the physician office, veterinary lab, and biopharmaceutical markets. Alfa Wassermann’s diagnostic technology products include the ACE Alera®, ACE Axcel®, and Vet Axcel® clinical chemistry analyzers that are sold around the world to physicians, veterinarians, research laboratories, and other such medical facilities, including many of the leading pharmaceutical companies, academic institutions, and animal conservatories.
For further information, please contact:
Tanya De Boer
Director of Marketing
# # #
All trademarks, service marks and company names are the property of their respective owners.